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Abstracts / Biol Blood Marrow Transplant 21 (2015) S54eS78S62(77%) evaluable patients had treatment success at 6 months.
Overall survival at 6 months was 97% (n¼35/36).
Conclusion: These data suggest that: FAMwaswell tolerated
and may halt pulmonary compromise in newly diagnosed
BOS and permit steroid reductions, which collectively
improve cGVHD outcomes and quality of life.Figure 1.
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Background: Chronic GVHD (cGVHD) remains the major
contributor to morbidity and mortality for survivors of
allogeneic hematopoietic cell transplant (HCT), but it
remains a clinical diagnosis.
Methods: We used a proteomics discovery approach
comparing plasma pools from onset of de novo cGVHD
(N¼17), progressive cGVHD (N¼18), and matched time-point
samples from 19 patients without GVHD. Of 105 proteins that
showed at least 1.3-fold change in the quantiﬁcation ratio,
we further selected 24 proteins based on their involvement
in relevant pathway networks, and the availability of ELISA.
In addition, two markers (CXCL9 and ST2) were measured
based on previously noted associations with cGVHD or
refractory acute GVHD.
Levels of these 26 proteins were measured by ELISA in
plasma from an independent set of 178 patients with cGVHD,
and from 33 controls without cGVHD. Logistic regressionwas
used to evaluate the association between cGVHD and
biomarkers after log transformation. All analyses were
adjusted for signiﬁcant clinical variables considering age, sex,
stem cell source, conditioning (nonmyeloablative vs. others),
donor (matched sibling vs. others), and time from HCT to
sample collection. To determine the best combinationmodel,
we used forward selectionwith a 0.05 signiﬁcance threshold,
conﬁrmed by backward selection. ROC curves were
generated for the best single biomarker, and the combination
model. The analysis of nonrelapse mortality (NRM) divided
the panel weighted sum on the median value among cGVHD
cases (N ¼ 178), and compared cases above and below the
median.
Results: Of the 26 proteins tested, 9 were associated with






ST2 0.832 <0.0001 <0.0001 Yes
MMP3 0.787 <0.0001 <0.0001 Yes
TRAILR3 0.716 0.0002 0.0002
OPN 0.708 <0.0001 <0.0001 Yes
SELP 0.661 0.008 0.005
CKIT 0.654 0.007 0.01
COMP 0.643 0.009 0.002
CXCL9 0.628 0.02 0.01 Yes
CD146 0.616 0.03 0.04
Combination 0.885 <0.0001 <0.0001
Figure 3.MMP3, and OPN compose a biomarker panel for diagnosis of
cGVHD with an AUC of 0.89 (Fig 1). We next compared
the biomarker panel between groups with different
cGVHD severity (none, mild/moderate, severe) (Fig 2).
Severity of cGVHD was associated with the biomarker
panel (p<0.0001 compared to control, and p¼0.007
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between groups with high vs. low biomarker levels,
showing that the biomarker panel predicted NRM [Hazard
Ratio¼11.4, p¼0.002 (adjusted)] (Fig 3).
We conclude that ST2, CXCL9, MMP3, and OPN represent
a biomarker panel for reliable, non-invasive diagnosis of
cGVHD as well as for correlation with cGVHD severity, and
prediction of NRM. Once further validated, these biomarkers
could help identify patients with cGVHD at risk for poor
outcomes with current treatment approaches.48
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Graft-versus-host disease (GVHD) remains the major
barrier to the success of allogeneic stem cell transplantationFigure 1. Anti-ST2 mAb treatment reduces GVHD severity and mortality by increas
allogeneic group. Mice were treated with anti-ST2 or lgG isotype control via intraper
GVHD score and (C) histopathologic analysis shows protection from GVHD in anti-ST2
modutates transcript expression in MLN T cells. *pc<0.05**p<0.01, ***p<0.001, IgG vs(SCT). We have reported that soluble suppression of tumori-
ginicity 2 (ST2) measured in plasma of post-SCT patients is a
marker for risk of therapy-resistant GVHD and death. ST2 is a
member of the IL-1 receptor family whose sole known ligand
is IL-33. Soluble ST2 acts as a decoy receptor for IL-33. Thus,
we hypothesized that blockade of soluble ST2 will increase
the amount of free IL-33 that will be able to bind to
membrane ST2 on CD4+ T cells, driving them toward a Th2
phenotype, which will alleviate GVHD. First, we found that
similar to plasma ST2 course in SCT patients, plasma ST2 was
markedly increased prior to and at the onset of GVHD
symptoms in multiple clinically relevant GVHD murine
models (B6 to C3H.SW shown, Fig. 1A). Based on this obser-
vation, anti-ST2 antibody given with a prophylactic schedule
(one dose before SCT and one dose at day+1 post-SCT)
signiﬁcantly reduced GVHD severity and mortality (Fig. 1B).
Pathology analysis indicated that anti-ST2 treated recipients
showed lower histopathologic score in liver and intestine
(Fig. 1C). Strikingly, anti-ST2 signiﬁcantly increased plasma
IL-33 (Fig. 1D). Whole transcriptome analysis of mesenteric
lymph node T cells showed that anti-ST2 modulated gene
expression of helper T cell (Th1/Th2) related cytokines (Fig.
1E), suggesting that ST2 blockade may affect the helper T
cell compartment. To further assess the effects of
ST2 blockade on helper T cells, we examined the Th1/Th2ing plasma IL-33 (A) The kinetics of plasma sST2 show increased sST2 levels in
itoneal injection on Day 1 and Day 1 post-transplantation (B) Survival, clinical
treated group. (D) Increased plasma IL-33 in anti-ST2 treated group. (E)Anti-ST2
Anti-ST2.
